Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - Rennova Health, Inc.ex99_2.htm
EX-99.1 - EXHIBIT 99.1 - Rennova Health, Inc.ex99_1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 11, 2014
 

 
CollabRx, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)
000-26824
(Commission
File Number)
68-0370244
(I.R.S. Employer
Identification No.)

44 Montgomery Street, Suite 800
San Francisco, CA 94104-4811
 (Address of Principal Executive Offices)

(415) 248-5350
 (Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 



Item 2.02.
Results of Operations and Financial Condition

On February 11, 2014, CollabRx, Inc. (the “Company”) issued its third quarter fiscal year 2014 press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K and incorporated by reference herein. On February 11, 2014, the Company held a conference call announcing its financial results for the third quarter fiscal year 2014. The transcript of this conference call is furnished as Exhibit 99.2 to this Form 8-K and is incorporated by reference herein.

Item 9.01
Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.Description

99.1 Press Release dated February 11, 2014

99.2 Transcript of CollabRx Inc.’s third quarter fiscal year 2014 conference call held on February 11, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  February 12, 2014
 
COLLABRX, INC.
 
 
By:
/S/ Thomas R. Mika
 
Name:
Thomas R. Mika
 
Title:
President and Chief Executive Officer